Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity

Journal of Immunology

Volumn 174, Issue 6, 2005, Pages 3808-3817

  He, Yukai ^a   Zhang, Jiying ^a   Mi, Zhibao ^a   Robbins, Paul ^a   Falo Jr , Louis D ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GAMMA INTERFERON; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; PEPTIDE; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSFECTION; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 14844351569     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.6.3808     Document Type: Article

References (72)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Thompson, A. G., and R. Thomas. 2002. Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol. Cell. Biol. 80:509.
3. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
4. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, and A. B. Deleo. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
5. Carbone, F. R., and M. J. Bevan. 1990. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171:377.
6. Falo, L. D., Jr., M. Kovacsovics-Bankowski, K. Thompson, and K. L. Rock. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:649.
7. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243.
8. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
9. Celluzzi, C. M., and L. D. Falo, Jr. 1998. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160:3081.
10. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
11. Ridgway, D. 2003. The first 1000 dendritic cell vaccinees. Cancer Inves. 21:87-3.
12. Ardavin, C., S. Amigorena, and C. Reis e Sousa. 2004. Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20:17.
13. Berzofsky, J. A., M. Terabe, S. Oh, I. M. Belyakov, J. D. Ahlers, J. E. Janik, and J. C. Morris. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113:1515.
14. Gilboa, E. 2004. The promise of cancer vaccines. Nat. Rev. Cancer 4:401.
15. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475.
16. Amoscato, A. A., D. A. Prenovitz, and M. T. Lotze. 1998. Rapid extracellular degradation of synthetic class I peptides by human dendritic celts. J. Immunol. 161:4023.
17. Kukutsch, N. A., S. Rossner, J. M. Austyn, G. Schuler, and M. B. Lutz. 2000. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J. Invest. Dermatol. 115:449.
18. Zehn, D., C. J. Cohen, Y. Reiter, and P. Walden. 2004. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Eur. J. Immunol. 34:1551.
19. Rescigno, M., S. Citterio, C. Thery, M. Rittig, D. Medaglini, G. Pozzi, S. Amigorena, and P. Ricciardi-Castagnoli. 1998. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. [Published erratum appears in 1999 Proc. Natl. Acad. Sci. USA 96:9666.] Proc. Natl. Acad. Sci. USA 95:5229.
20. Rescigno, M., S. Citterio, C. Thery, M. Rittig, D. Medaglini, G. Pozzi, S. Amigorena, and P. Ricciardi-Castagnoli. 1998. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. [Published erratum appears in 1999 Proc. Natl. Acad. Sci. USA 96:9666.] Proc. Natl. Acad. Sci. USA 95:5229.
21. + dendritic cells but not by Langerhans cells. Science 301:1925.
22. Motta, I., F. Andre, A. Lim, J. Tartaglia, W. I. Cox, L. Zitvogel, E. Angevin, and P. Kourilsky. 2001. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J. Immunol. 167:1795.
23. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:1685.
24. + T cells and antiviral immunity. Immunity 20:47.
25. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304:1314.
26. + T cell cross-priming via transfer of proteasome substrates. Science 304:1318.
27. Shen, L., and K. L. Rock. 2004. Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 101:3035.
28. Kirk, C. J., and J. J. Mule. 2000. Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene Ther. 11:797.
29. Arthur, J. F., L. H. Butterfield, M. D. Roth, L. A. Bui, S. M. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. H. McBride, and J. S. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17.
30. Pecher, G., G. Spahn, T. Schirrmann, H. Kulbe, M. Ziegner, J. A. Schenk, and V. Sandig. 2001. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anticancer Res. 21:2591.
31. Zhong, L., A. Granelli-Piperno, Y. Choi, and R. M. Steinman. 1999. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:964.
32. Morelli, A. E., A. T. Larregina, R. W. Ganster, A. F. Zahorchak, J. M. Plowey, T. Takayama, A. J. Logar, P. D. Robbins, L. D. Falo, and A. W. Thomson. 2000. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway. J. Virol. 74:9617.
33. + T cells: implications for an efficient vaccination strategy. Gene Ther. 10:243.
34. Takayama, T., Y. Nishioka, L. Lu, M. T. Lotze, H. Tahara, and A. W. Thomson. 1998. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 66:1567.
35. Chinnasamy, N., D. Chinnasamy, J. F. Toso, R. Lapointe, F. Candotti, R. A. Morgan, and P. Hwu. 2000. Efficient gene transfer to human peripheral biood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum. Gene Ther. 11:1901.
36. Metharom, P., K. A. Ellem, C. Schmidt, and M. Q. Wei. 2001. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther. 12:2203.
37. Firat, H., V. Zennou, F. Garcia-Pons, F. Ginhoux, M. Cochet, O. Danos, F. A. Lemonnier, P. Langlade-Demoyen, and P. Chameau. 2002. Use of a lentiviral flap vector for induction of CTL immunity against melanoma: perspectives for immunotherapy. J. Gene Med. 4:38.
38. Zarei, S., F. Leuba, J. F. Arrighi, C. Hauser, and V. Piguet. 2002. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. J. Allergy Clin. Immunol. 109:988.
39. Esslinger, C., P. Romero, and H. R. MacDonald. 2002. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 13:1091.
40. Breckpot, K., M. Dullaers, A. Bonehill, S. van Meirvenne, C. Heirman, C. de Greef, P. van der Bruggen, and K. Thielemans. 2003. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med. 5:654.
41. Lizee, G., M. I. Gonzales, and S. L. Topalian. 2004. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther. 15:393.
42. Dull, T., R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463.
43. Zufferey, R., T. Dull, R. J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873.
44. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270.
45. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
46. + T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J. Immunol. 164:1243.
47. Larregina, A. T., A. E. Morelli, O. Tkacheva, G. Erdos, C. Donahue, S. C. Watkins, A. W. Thomson, and L. D. Falo, Jr. 2004. Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation. Blood 103:811.
48. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu. and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
49. Follenzi, A., L. E. Ailles, S. Bakovic, M. Geuna, and L. Naldini. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217.
50. Follenzi, A., and L. Naldini. 2002. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346:454.
51. Reiser, J. 2000. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 7:910.
52. + T cell responses. J. Clin. Invest. 111:1673.
53. Stock, A. T., S. N. Mueller, A. L. van Lint, W. R. Heath, and F. R. Carbone. 2004. Cutting edge: prolonged antigen presentation after herpes simplex virus-1 skin infection. J. Immunol. 173:2241.
54. Wu, T. C., F. G. Guarnieri, K. F. Staveley-O'Carroll, R. P. Viscidi, H. I. Levitsky, L. Hedrick, K. R. Cho, J. T. August, and D. M. Pardoll. 1995. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA 92:11671.
55. Hegde, N. R., M. S. Chevalier, and D. C. Johnson. 2003. Viral inhibition of MHC class II antigen presentation. Trends Immunol. 24:278.
56. Alcami, A., P. Ghazal, and J. W. Yewdell. 2002. Viruses in control of the immune system: workshop on molecular mechanisms of immune modulation: lessons from viruses. EMBO Rep. 3:927.
57. Yewdell, J. W., and A. B. Hill. 2002. Viral interference with antigen presentation. Nat. Immunol. 3:1019.
58. VandenDriessche, T., L. Naldini, D. Collen, and M. K. Chuah. 2002. Oncoretroviral and lentiviral vector-mediated gene therapy. Methods Enzymol. 346:573.
59. Sumimoto, H., T. Tsuji, H. Miyoshi, M. Hagihara, R. Takada-Yamazaki, S. Okamoto, Y. Ikeda, T. Takahashi, and Y. Kawakami. 2002. Rapid and efficient generation of lentivirally gene-modified dendritic cells from DC progenitors with bone marrow stromal cells. J. Immunol. Methods 271:153.
60. Rouas, R., R. Uch, Y. Cleuter, F. Jordier, C. Bagnis, P. Mannoni, P. Lewalle, P. Martial, and A. Van den Broeke. 2002. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Ther. 9:715.
61. Manganini, M., M. Serafini, F. Bambacioni, C. Casati, E. Erba, A. Follenzi, L. Naldini, S. Bernasconi, G. Gaipa, A. Rambaldi, et al. 2002. A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum. Gene Ther. 13:1793.
62. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
63. Gilboa, E., and J. Vieweg. 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199:251.
64. Dullaers, M., K. Breckpot, S. Van Meirvenne, A. Bonehill, S. Tuyaerts, A. Michiels, L. Straetman, C. Heirman, C. De Greef, P. Van Der Bruggen, et al. 2004. Side-by-side comparison of lentivirally transduced and MRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol. Ther. 10:768.
65. + T cell responses to malaria liver stages. Proc. Natl. Acad. Sci. USA 99:11819.
66. Wong, P., and E. G. Pamer. 2003. Feedback regulation of pathogen-specific T cell priming. Immunity 18:499.
67. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161:897.
68. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61:8643.
69. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823.
70. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25:207.
71. Rubinstein, N., M. Alvarez, N. W. Zwirner, M. A. Toscano, J. M. Ilarregui, A. Bravo, J. Mordoh, L. Fainboim, O. L. Podhajcer, and G. A. Rabinovich. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5:241.
72. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5:508.